Background: Arginine-specific (RgpB and RgpA) and lysine-specific (Kgp) gingipains are secretory cysteine proteinases of Porphyromonas gingivalis that act as important virulence factors for the organism. They are translated as zymogens with both N-and C-terminal extensions, which are proteolytically cleaved during secretion. In this report, we describe and characterize inhibition of the gingipains by their N-terminal prodomains to maintain latency during their export through the cellular compartments. General significance: Blocking progingipain activation may offer an attractive strategy to attenuate P. gingivalis pathogenicity.
Introduction
Proteolysis plays a key role in all aspects of life processes. Since peptide bond hydrolysis is irreversible, proteolytic enzymes are tightly regulated spatially and temporally at the transcriptional and post-translational levels [1] . The latter is accomplished by many mechanisms and is well characterized in eukaryotes. Perplexingly, far less is known about post-translational control of proteolysis in prokaryotes although many of them produce copious amounts of proteases. Due to the broad specificity of many secreted enzymes, bacterial extracellular proteases are often synthesized as enzymatically inactive proforms (zymogens) [2, 3] . The zymogenic status is frequently exerted by an N-terminal profragment functioning as a tethered inhibitor, which needs to be removed by proteolysis to release the active protease [4- lysate was clarified by ultracentrifugation at 150,000 # g for 1 hour before being passed through a pre-equilibrated glutathione-Sepharose TM High Performance column (GE Healthcare, Pittsburgh, PA, USA) at room temperature. Recombinant GST-PDs were eluted using 50 mM Tris-HCl, pH 8.0, supplemented with 10 mM reduced glutathione. After overnight dialysis against 4 L of PBS, samples were incubated for 24 hours at 4 °C with the PreScission TM Protease (GE Healthcare) and subjected again to chromatography on glutathione-Sepharose TM to remove GST and uncleaved GST-PD fusion proteins. The flow-through was concentrated by ultrafiltration using a 10 kDa cut-off membrane and dialyzed against PBS. Protein concentration was determined by BCA Assay (Sigma) and purity of recombinant protein was verified by SDS-PAGE electrophoresis (NuPAGE R 4-12% Bis-Tris Gel, Invitrogen) stained with SimplyBlue TM SafeStain (Invitrogen).
The wild-type plasmid construct of PD-RgpB was used to produce Arg66Lys (R66K), Arg66Ala (R66A), Arg102Lys (R102K), Arg102Ala (R102A), Arg102Glu (R102E) and Arg102Gln
(R102Q), and Arg159Lys (R159K) mutations using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following the manufacturer's instructions. The mutated constructs were verified by DNA sequencing.
CD spectroscopy
CD spectra of PDs at 0.3 mg/ml in 20 mM sodium phosphate buffer, pH 7.4, were obtained using a Jasco J-710 spectropolarimeter with 1 mm cell pathlength. Data acquisitions were made at 0.2 nm intervals with a dwell time of 1 s between 200 and 260 nm, at 20 °C and averaged from 4 repeated scans. Secondary-structure content was assessed from CD measurements by computational analysis based on Kohonen's self-organizing maps: SOMCD [36] and compared to the predicted secondary-structure content estimated by Jpred 3 [37] .
aminopeptidase activity of RgpB and HRgpA was determined under the same condition using the fluorogenic substrate H-Arg-AMC (" ex = 380 nm; " em = 460 nm) [38] . Similarly, inhibition of proteolytic activity in 10 nM gingipains by PDs was determined using 100 µl of 15 mg/ml suspension of Azocoll substrate under the same condition as described above. After 2 hours at 37 °C, the reaction was stopped by addition of 100 µl of 3 M Glycine, pH 3.0 and undigested Azocoll fibers were removed by centrifugation (5 min at 10,000 # g). The absorbance at 520 nm of the clarified supernatant (200 µl) was measured in a 96-well plate using a SpectraMax M5 spectrofluorimeter plate-reader.
Determination of the inhibition mode and kinetic measurement
RgpB and HRgpA (1 nM) were incubated at 37 °C in assay buffer supplemented with 10 mM L-cysteine in the presence of increasing concentrations of PD (0 to 10 nM) in a 96-well plate.
After 15 min, the fluorogenic substrate Z-Arg-AMC was added at several concentrations (0 to 30 µM) and the residual activities were recorded (" exc = 380 nm; " em = 460 nm) on a spectrofluorimeter plate-reader SpectraMax M5. The type of enzyme inhibition was determined graphically using the Lineweaver-Burk plot according to the equation (1).
where V is the reaction velocity, V max the maximum reaction velocity, K m the Michaelis-Menten constant and [S] the substrate concentration.
The inhibition constant K i was determined by a curve fitting using Graph Pad Prism software (La Jolla, USA) to the Dixon plot for non-competitive inhibition according to the equation (2) .
where [I] is the inhibitor concentration.
The rate constant for association (k ass ) was determined by monitoring the time dependence of association of gingipains with the PDs. Enzymes (10 nM) were incubated at 37 °C with increasing concentrations of PD in the gingipain assay buffer supplemented with L-cysteine and residual enzymatic activity was measured as a function of time after addition of Z-Arg-AMC (50 µM). The k ass was determined by non-linear regression plotting
(Graph Pad Prism software, La Jolla, USA).
The dissociation rate constant (k diss ) was calculated from the experimental values of K i and k ass according to the equation (3). 10/300 GL (GE Healthcare) using an AKTA purifier 900 FPLC system (GE Healthcare) at a flow rate of 0.25 ml/min. Elution profile was followed at 280 nm and 0.5 ml fractions were collected. of RgpB were resolved by Native-PAGE using 12% gels.
Bacteria cultivation and characterization
Porphyromonas gingivalis strains were grown in enriched tryptic soy broth (eTSB) (30 g/L Trypticase soy broth, 5 g/L yeast extract, 5 mg/L hemin, 2 mg/L menadione supplemented with 5 mM L-cysteine, pH 7.5) in an anaerobic chamber (Bactron IV; Sheldon Manufacturing Inc., OR) in an atmosphere of 90% N 2 , 5% CO 2 , and 5% H 2 . Cultures cultivated into the stationary phase of growth were adjusted to the same OD 600 1.5 and centrifuged at 5,000 # g for 10 min.
Supernatants were collected and pellets were washed and resuspended in PBS to the original volume to obtain the cells fraction. In supernatants and cell suspensions, the presence of RgpB was determined by Western-blotting with specific rabbit pAbs anti-RgpB while the gingipain activity was measured at 37 °C using L-BAPNA substrate as described earlier.
Inhibition of different cellular forms of RgpB by PD
Whole cultures of P. gingivalis strains W83, HG66, RgpA-C and RgpB-6HTSI were grown to early stationary phase and the cellular fraction was separated from the cell-free media by centrifugation as above. Washed bacterial cell suspension or cell-free culture media were incubated at 37 °C in assay buffer supplemented with 10 mM L-cysteine in the presence of increasing concentrations of PD RgpB (0.1 nM to 10 µM) in a 96-well plate. In each case, cultures or culture-derived fractions were adjusted to have Rgp activity equivalent to 10 nM of purified RgpB. After 15 min, the residual gingipain activity was determined using L-BAPNA as the substrate. The IC 50 was determined using Graph Pad Prism software.
Results

Rgps, but not Kgp, are inhibited by N-terminal prodomain
We have previously shown that when expressed in yeast, proRgpB rapidly undergoes autoproteolytic processing at the N-and C-termini to yield fully active enzyme. Therefore, we have concluded that N-terminal prodomain (PD) allows low level of latency to proRgpB [39] . To revisit the role of the PD in the control of gingipain activity, we used recombinant PDs derived from RgpA, RgpB, and Kgp to investigate their interactions with the mature proteases ( 
RgpB forms stable stoichiometric inhibitory complexes with profragments
To further investigate PD interaction with RgpB, we assessed complex stability and reaction stoichiometry by native PAGE. A complex formed by equimolar concentration of the negatively charged RgpB CD (pI 4.95) and the cationic PD RgpB (pI 8.06) migrated with significantly slower electrophoretic mobility than free RgpB. Of note, PD RgpB did not penetrate into the gel in native PAGE conditions due to its high pI. A shift of RgpB-PD RgpB complex to a lower mobility band was confirmed by Western blot analysis ( Fig. 2A) . Conversely, no complex formation was detected between RgpB and PD Kgp ( Table 1 ).
Formation of the 1:1 stoichiometric complex between RgpB and its PD was confirmed by size exclusion chromatography. At a slight molar excess of PD RgpB to RgpB and in the presence of L-cysteine, a peak containing both proteins was eluted from the Superdex 200 column at the volume equivalent to the molecular mass of the complex (62 kDa) (Fig. 3AB) . By contrast, in the absence of cysteine, even at four molar excess of PD RgpB , a portion of RgpB did not form the complex. This is apparently due to reversible modification of cysteine residue(s) in RgpB with dithiodipyridine used during gingipain purification.
Finally, the stability of the complex was tested by incubation of the proformed complex at room temperature. At 5 molar excess of PD RgpB over RgpB, no gingipain activity was released up to 96h incubation despite the clear decrease of intensity of a band corresponding to PD RgpB in SDS-PAGE (Fig. 4A) . The apparent reduction of molecular mass of PD was due to cleavage at the N-terminus of the PD (GPLGSQPAER#GRN….). The truncation, however, did not affect the complex stability as shown by native PAGE (Fig. 4B ). The depletion of PD and timedependent truncation was also observed in the complex formed with the large excess of PD.
This suggests that RgpB in the complex retains some in trans activity responsible for degradation of the excess of free PD and truncation of the PD in the complex but is unable to degrade attached PD in cis and escape from the inhibitory complex.
Collectively these results indicate that PDs derived from RgpA and RgpB form very stable 1:1 stoichiometric inhibitory complexes with their cognate mature gingipains only. Therefore they can prevent premature release of gingipain activity in the P. gingivalis periplasm.
Profragments are non-competitive reversible inhibitors of the mature gingipains
To determine the mode of inhibition, we performed a kinetic analysis of RgpB and HRgpA interaction with their PDs. The inhibition followed the Michaelis-Menten kinetic and was dependent on the concentration of PD and the substrate concentration (Fig. 5AB) indicating the reversible mode of inhibition. This was confirmed by re-plotting the kinetic data using the Lineweaver-Burk equation, which revealed the formation of non-competitive, reversible inhibitory complexes (Fig. 5CD) . Finally, the steady-state inhibition constant (K i ) was determined graphically using the Dixon plot for non-competitive inhibition (Fig. 5EF) . The results of kinetic analysis of inhibition (K i , k ass , and k dis ) are summarized in Table 2 showing that PDs are very efficient, low nanomolar inhibitors of mature gingipains with K i in the range from 0.85 to 6.2 nM.
In concordance with IC 50 values (Table 1) , HRgpA was more efficiently inhibited by PDs than RgpB.
Rgps inhibition by PDs depends on Arg 102
Alignment of gingipain prodomain sequences revealed a conservation of Arg or Lys residues at (RgpB-equivalent) positions 66, 102 and 159 in PD Rgps and PD Kgp , respectively (Fig. S1 ). In consideration of each gingipain's specificity, we hypothesized that one of these conserved residue functions as the P1 inhibitory residue of the profragments. To verify this hypothesis, we have expressed PD RgpB with the following mutations: R66K, R66A, R102K, R102A, R102E, R102Q and R159K. As shown in Table 3 , mutation of Arg-102 had a strong impact on the inhibitory activity of PD RgpB . While the R102K mutant exhibited a one log reduced efficiency to inhibit RgpB, Arg-102 substitution with Ala, Glu, Gln totally abolished its inhibitory activity. In contrast, mutations of other Arg residues had relatively low (R66K) or no effect (R66K and R159K) on the PD inhibitory property. Significantly, none of Arg to Lys mutation converted PD RgpB into even a weak inhibitor of Kgp (data not shown). The CD spectra analysis of mutated PDs was found to be identical to the spectrum of the native PD with the exception of the R66K
variant showing some increase in #-helix content at the expense of !-sheet content (Fig. S2 ).
This suggests the observed decrease in inhibitory capacity of R66K is most likely due to some minor structural changes. Together, these results strongly implicate Arg-102 as the P1 residue in the inhibitory interaction between PD and Rgps. This is in agreement with a previous observation of PD RgpB cleavage at Arg-102 during the activation/maturation process of recombinant proRgpB expressed in yeast cells [39] .
The stable complex formation occurs via profragment interaction independent of the catalytic cysteine residue
Dependence of the PD RgpB -RgpB complex formation on the pretreatment of RgpB with reducing agents (Fig. 1) and reversible abrogation of the interaction with a cysteine-modifying reagent dithiodipyridine (data not shown), suggests that the reduced catalytic Cys449 is essential for inhibitory interactions. Unexpectedly, however, we found that pretreatment of RgpB with an irreversible inhibitor (TLCK) to covalently modify Cys449 did not affect the inhibitory complex formation as assessed by gel filtration, native PAGE and Western blotting (Fig. 6) . Similarly, blocking the RgpB catalytic cysteine with FR-FMK had no significant effect on the interaction between RgpB and PD RgpB . In stark contrast, however, pretreatment of RgpB with chloromethylketone inhibitors carrying three amino acid residues (Z-FFR-CMK and YPR-CMK), strongly interfered with the complex formation. As shown by gel filtration, RgpB inactivated by these chloromethylketones was eluted predominantly as the free enzyme accompanied by a small amount of the complex (Fig. 6A) . The minimal complex formation between Z-FFR-CMK and YPR-CMK-treated RgpB and PD RgpB was confirmed by native PAGE (Fig. 6B) . Together, these findings argue that interaction with the catalytic Cys449 is not involved in complex formation. Conversely, the presence of the P3 and P2 residues of the tripeptide inhibitors interfering with the complex formation suggests PD RgpB inhibits RgpB through interactions with non-primed substrate binding subsites on the protease moiety.
The lack of engagement of Cys449 in the RgpB inhibition by PD is compatible with the noncompetitive mechanism of inhibition observed using Z-Arg-AMC as the substrate (Fig. 5) .
However, the strong interference with PD RgpB -RgpB complex formation by covalent inhibitors with three amino acid residues suggests that the inhibition mode would be different if RgpB residual activity is assayed using longer substrates interacting with S2 and S3 binding subsites.
To verify this contention, we re-analyzed the kinetics of RgpB inhibition by PD RgpB using Z-FR-AMC, Z-GPR-AMC and Z-AGPR-AMC as the substrates. In agreement with the prediction, the mode of inhibition shifted from non-competitive to partially competitive inhibition, the latter especially evident with the longest substrate (Fig. 7) .
Prodomain weakly inhibits cell-associated or glycosylated forms of gingipains
Rgps occurs in different forms, including highly glycosylated cell-associated RgpB (membrane-type RgpB; mt-RgpB), RgpA-Kgp complex on the cell surface and soluble enzymes released into the culture media. To assess how these forms interact with PD RgpB , we have determined IC 50 of inhibition of Rgps in whole cultures and cell-free culture media of different P.
gingivalis strains. Of note, in all cases, Rgp activity was adjusted to be equivalent to 10 nM concentration of the purified, active-site titrated RgpB. As a control to evaluate the effect of growth media and bacterial cells on gingipain interaction with PD RgpB , purified RgpB was spiked into sterile medium and subcellular fractions (whole culture, cell-free culture supernatant, and washed cells) derived from the culture of a gingipain-null strain. Regardless of the strain, soluble, non-glycosylated Rgps in cell-free culture media were inhibited with the same potency as the purified enzyme (IC 50 in the range from 0.011 to 0.022 µM) (Table 4 ). However, in the presence of bacterial cells (whole cultures of strains secreting non-glycosylated gingipains into the media or spiked with purified RgpB) the IC 50 of inhibition was increased by one log (in the range from 0.116 to 0.128 µM). This decrease in potency of Rgps inhibition by PD RgpB in the presence of P. gingivalis cells was not due to PD RgpB binding to or being degraded by the bacterial cells because the level of recovered PD RgpB in the supernatant remained constant after the cells were removed by centrifugation (Fig. S3) . Finally, cell-associated Rgps were fairly resistant to inhibition by PD RgpB (IC 50 > 1 µM). This resistance is partly dependent on gingipain glycosylation since purified, membrane-type highly glycosylated RgpB was still five times more susceptible to inhibition by PD RgpB (IC 50 = 0.188 µM) than cell-associated enzyme (Table 4) .
Collectively, these results suggest that once Rgps are secreted, PD cleavage in the context of P. gingivalis cells will lead to dissociation of the PD from the complex to release active gingipains into the extracellular environment. Of note, recombinant PD RgpB added to the culture medium had no effect on P. gingivalis growth (Fig. S4 ).
Discussion
In prokaryotes and eukaryotes, amino-terminal prodomains of enzymes are commonly observed to exert temporal and/or spatial control over proteolytic activity to maintain latency of secreted proteases [1, 40] . Prodomains have also been reported to play the role of tethered chaperones assisting protein folding in cis [41, 42] . Inhibition of cysteine proteases by PDs is accomplished in several different ways. In lysosomal cathepsins (family C1 of cysteine proteases), a C-terminal segment of a structurally related PD binds in an extended conformation covering the entire active site cleft in an opposite orientation to that of substrate binding [43] . In staphopain A (family C47) of Staphylococcus aureus, PD also binds in the opposite orientation to substrates, but occludes only the primed sites in the active site cleft of the protease [8] .
RgpB by PD RgpB is changed to the mixed inhibition type when tri-and tetrapeptide-substrates are used to measure the gingipain residual activity suggesting that longer substrates are less likely to compete with PD for the substrate-binding cleft. This is corroborated by the finding that pretreatment of RgpB with irreversible active-site inhibitors, which covalently bind to catalytic Cys244 S$ through methylene group [46] , variably affected formation of the RgpB-PD RgpB complex. While TLCK and FR-FMK exerted no effect on stable complex formation, tripeptidyl inhibitors YPR-CMK and Z-FFR-CMK entirely blocked the interaction. As similar interaction must take place during PD RgpB interaction with FR-FMK pretreated RgpB and the Arg residue of covalently bound FR-FMK must be replaced by Arg-102 to allow for stable complex formation. This is apparent from the finding that R102A, R102E and R102Q mutants of PD have no inhibitory activity while conservative replacement of Arg-102 with Lys reduces PD RgpB affinity by one log. Directed mutagenesis of other conserved Arg residues had no effect on inhibitory activity of PD RgpB . In the case of longer inhibitors, additional interactions of P3 and P4 residues Alternatively, the Kgp latency may be dependent on the C-terminal extension while PD Kgp has a different function as described for PDs of other cysteine and serine proteases, such as an intramolecular chaperone.
Previously, we have found that the full-length RgpB zymogen expressed in Saccharomyces cerevisiae strain YG227 rapidly auto-processed itself via an intermolecular mechanism (where a different catalytic site attacks the bonds in an adjacent molecule). Based on the analysis of the processing, we concluded that the N-terminal PD and C-terminal extension render a low amount of latency and the zymogen was substantially active [39] . This conclusion is in conflict with numerous reports showing that P. gingivalis strains deficient in the PorSS secretion system accumulate in the periplasm large amounts of proteolytically inactive full-length and partially processed progingipains, including proRgpB [21, 27-31, 47, 48] . In the recombinant proRgpB, [48] and the mature protease is either glycosylated to be retained on the bacterial surface or released as a soluble form into the growth medium. In any case, failure of PD RgpB to efficiently inhibit cell-associated Rgps (Table 4) argues that a mechanism exist to release active gingipains from the complex outside the cell, thus, protecting the periplasm against potentially deleterious effect of prematurely activated enzymes. and stained with SimplyBlue TM SafeStain. C) CD of PD RgpA (!), PD Kgp (!), and PD RgpB (").
D)
Comparison of residues numbers, molecular mass, pI, shared percentage of identity of primary structure and the content of secondary structure elements theoretical vs. calculated from CD spectra.
Fig. A.2. CD spectra analysis of PD RgpB mutants
CD spectra were obtained as described in Fig. S1 . The table below the graph compares the content of #-helix and !-sheet in individual mutants of PD. 
